Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene Autoleucel Retreatment in B-cell Lymphoma
NCT05814848Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2023
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 4 trial of relmacabtagene autoleucel in B cell lymphoma, sponsored by Changhai Hospital. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05814848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814848.